Studies on the effect of p300 inhibitors on transcriptional regulation have found that treatment of multiple myeloma cells with A485 preferentially enables the deacetylation of enhancer progenitor-associated histones at the transcriptional level [69]. This evidence concerns the gene EP300 and plasma cell myeloma.